

SIERRA LEONE – Pentavalent vaccine support

This decision letter sets out the programme terms of a programme.

1. Country: Sierra Leone																		
2. Grant number: 16-SLE-04c-X																		
3. Date of decision letter: 20 November 2015																		
4. Date of the Partnership Framework Agreement: 31 October 2013																		
5. Programme title: New vaccine support (NVS), Pentavalent Routine																		
6. Vaccine type: Pentavalent																		
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID																		
8. Programme duration¹: 2007 -2016																		
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)																		
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 20%;">2007-2015</th> <th style="width: 20%;">2016</th> <th style="width: 30%;">Total²</th> </tr> </thead> <tbody> <tr> <td style="padding: 5px;">Programme budget (US\$)</td> <td style="padding: 5px; text-align: right;">US\$15,931,635³</td> <td style="padding: 5px; text-align: right;">US\$1,314,500</td> <td style="padding: 5px; text-align: right;">US\$17,246,135</td> </tr> </tbody> </table>		2007-2015	2016	Total ²	Programme budget (US\$)	US\$15,931,635 ³	US\$1,314,500	US\$17,246,135										
	2007-2015	2016	Total ²															
Programme budget (US\$)	US\$15,931,635 ³	US\$1,314,500	US\$17,246,135															
10. Vaccine introduction grant (in US\$): . Not applicable																		
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement, if applicable) ⁴																		
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 45%;"></th> <th style="width: 25%;">2007-2015</th> <th style="width: 30%;">2016</th> </tr> </thead> <tbody> <tr> <td style="padding: 5px;">Type of supplies to be purchased with Gavi funds in each year</td> <td></td> <td></td> </tr> <tr> <td style="padding: 5px;">Number of Pentavalent vaccines doses</td> <td></td> <td style="text-align: right;">694,000</td> </tr> <tr> <td style="padding: 5px;">Number of AD syringes</td> <td></td> <td style="text-align: right;">771,900</td> </tr> <tr> <td style="padding: 5px;">Number of safety boxes</td> <td></td> <td style="text-align: right;">8,500</td> </tr> <tr> <td style="padding: 5px;">Annual amounts (US\$)</td> <td style="text-align: right;">US\$15,931,635⁵</td> <td style="text-align: right;">US\$1,314,500</td> </tr> </tbody> </table>		2007-2015	2016	Type of supplies to be purchased with Gavi funds in each year			Number of Pentavalent vaccines doses		694,000	Number of AD syringes		771,900	Number of safety boxes		8,500	Annual amounts (US\$)	US\$15,931,635 ⁵	US\$1,314,500
	2007-2015	2016																
Type of supplies to be purchased with Gavi funds in each year																		
Number of Pentavalent vaccines doses		694,000																
Number of AD syringes		771,900																
Number of safety boxes		8,500																
Annual amounts (US\$)	US\$15,931,635 ⁵	US\$1,314,500																
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.																		
13. Self-procurement: Not applicable.																		

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 16-SLE-04c-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	85,000
Value of vaccine doses (US\$)	US\$152,447
Total co-financing payments (US\$) (including freight)	US\$156,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable.

18. Other conditions: Not applicable.

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

20 November 2015

SIERRA LEONE – Pneumococcal vaccine support

This decision letter sets out the programme terms of a programme.

1. Country: Sierra Leone			
2. Grant number: 16-SLE-12c-X			
3. Date of decision letter: 20 November 2015			
4. Date of the Partnership Framework Agreement: 31 October 2013			
5. Programme title: New vaccine support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
8. Programme duration¹: 2010 -2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2010-2015	2016	Total ²
Programme budget (US\$)	US\$18,954,252 ³	US\$2,903,500	US\$ 21,857,752
10. Vaccine introduction grant (in US\$): . Not applicable			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2010-2015	2016	
Number of Pneumococcal vaccines doses		577,800	
Number of AD syringes		642,000	
Number of safety boxes		7,075	
Annual amounts (US\$)	US\$18,954,252 ⁵	US\$2,903,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable.			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.


³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

<p>14. Co-financing obligations: Reference code: 16-SLE-12c-X-C</p> <p>According to the co-financing policy, the Country falls within the group Initial self-financing.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2016</td> </tr> <tr> <td>Number of vaccine doses</td> <td>36,000</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$115,703</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>US\$123,000</td> </tr> </table>		Type of supplies to be purchased with Country funds in each year	2016	Number of vaccine doses	36,000	Value of vaccine doses (US\$)	US\$115,703	Total co-financing payments (US\$) (including freight)	US\$123,000
Type of supplies to be purchased with Country funds in each year	2016								
Number of vaccine doses	36,000								
Value of vaccine doses (US\$)	US\$115,703								
Total co-financing payments (US\$) (including freight)	US\$123,000								
<p>15. Operational support for campaigns: Not applicable</p>									
<p>16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>15 May 2016</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>		Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat		
Reports and other information	Due dates								
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat								
<p>17. Financial clarifications: Not applicable.</p>									
<p>18. Other conditions: Not applicable.</p>									

On behalf of Gavi



Hind Khatib-Othman
 Managing Director, Country Programmes

20 November 2015

SIERRA LEONE – Rotavirus vaccine support

This decision letter sets out the programme terms of a programme.

1. Country: Sierra Leone									
2. Grant number: 16-SLE-13b-X									
3. Date of decision letter: 20 November 2015									
4. Date of the Partnership Framework Agreement: 31 October 2013									
5. Programme title: New vaccine support (NVS), Rotavirus Routine									
6. Vaccine type: Rotavirus									
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule									
8. Programme duration¹: 2014 -2016									
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)									
<table border="1"> <thead> <tr> <th></th> <th>2014-2015</th> <th>2016</th> <th>Total²</th> </tr> </thead> <tbody> <tr> <td>Programme budget (US\$)</td> <td>US\$2,137,459³</td> <td>US\$1,047,000</td> <td>US\$3,184,459</td> </tr> </tbody> </table>		2014-2015	2016	Total ²	Programme budget (US\$)	US\$2,137,459 ³	US\$1,047,000	US\$3,184,459	
	2014-2015	2016	Total ²						
Programme budget (US\$)	US\$2,137,459 ³	US\$1,047,000	US\$3,184,459						
10. Vaccine introduction grant (in US\$): . Not applicable.									
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement) ⁴									
<table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Gavi funds in each year</th> <th>2014-2015</th> <th>2016</th> </tr> </thead> <tbody> <tr> <td>Number of Rotavirus vaccines doses</td> <td></td> <td>462,000</td> </tr> <tr> <td>Annual amounts (US\$)</td> <td>US\$2,137,459⁵</td> <td>US\$1,047,000</td> </tr> </tbody> </table>	Type of supplies to be purchased with Gavi funds in each year	2014-2015	2016	Number of Rotavirus vaccines doses		462,000	Annual amounts (US\$)	US\$2,137,459 ⁵	US\$1,047,000
Type of supplies to be purchased with Gavi funds in each year	2014-2015	2016							
Number of Rotavirus vaccines doses		462,000							
Annual amounts (US\$)	US\$2,137,459 ⁵	US\$1,047,000							
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.									
13. Self-procurement: Not applicable.									

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 16-SLE-13b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	46,500
Value of vaccine doses (US\$)	US\$99,027
Total co-financing payments (US\$) (including freight)	US\$102,000

15. Operational support for campaigns: Not applicable


16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable.

18. Other conditions: Not applicable.

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

20 November 2015

SIERRA LEONE – Measles vaccine support

This decision letter sets out the programme terms of a programme.

1. Country: Sierra Leone			
2. Grant number: 1516-SLE-09a-X			
3. Date of decision letter: 20 November 2015			
4. Date of the Partnership Framework Agreement: 31 October 2013			
5. Programme title: New vaccine support (NVS), Measles second dose Routine			
6. Vaccine type: Measles			
7. Requested product presentation and formulation of vaccine: Measles, 10 dose(s) per vial, LYOPHILISED			
8. Programme duration¹: 2015 -2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2015	2016	Total ²
Programme budget (US\$)	US\$54,000 ³	US\$76,500	US\$130,500
10. Vaccine introduction grant (in US\$): . Not applicable.			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2015	2016	
Number of Measles vaccines doses			216,900
Number of AD syringes			211,800
Number of re-constitution syringes			23,900
Number of safety boxes			2,600
Annual amounts (US\$)	US\$54,000 ⁵		US\$76,500
12. Procurement agency: UNICEF.			
13. Self-procurement: Not applicable.			
14. Co-financing obligations: Not applicable			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

15. Operational support for campaigns: Not applicable	
16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
18. Other conditions: Not applicable.	

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

20 November 2015

SIERRA LEONE – Yellow Fever vaccine support

This decision letter sets out the programme terms of a programme.

1. Country: Sierra Leone			
2. Grant number: 16-SLE-06b-X			
3. Date of decision letter: 20 November 2015			
4. Date of the partnership framework agreement: 31 October 2013			
5. Programme title: NVS, Yellow Fever Routine			
6. Vaccine type: Yellow Fever			
7. Requested product presentation and formulation of vaccine: Yellow Fever, 10 dose(s) per vial, LYOPHILISED			
8. Programme duration¹: 2003 -2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement)			
	2003-2015	2016	Total ²
Programme budget (US\$)	US\$2,330,090 ³	US\$220,500	US\$ 2,550,590
10. Vaccine introduction grant (in US\$): . Not applicable			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement): ⁴			
Type of supplies to be purchased with Gavi funds in each year	2003-2015	2016	
Number of Yellow Fever vaccines doses			199,700
Number of AD syringes			245,600
Number of re-constitution syringes			27,300
Number of safety boxes			3,025
Annual amounts (US\$)	US\$2,330,090 ⁵		US\$220,500
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable.			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 16-SLE-06b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	47,900
Value of vaccine doses (US\$)	US\$47,479
Total co-financing payments (US\$) (including freight)	US\$50,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable.

18. Other conditions: There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country.

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

20 November 2015